Efficacy
tumor
DISEASE, TUMOR
Preliminary efficacy was assessed using objective response rate (ORR) in patients with measurable disease, disease control rate (DCR) and progression-free survival (PFS), all in accordance with RECIST v1.1 [After initiation of treatment, tumor burden was assessed at baseline and every 8 weeks (± 1 week) for the qd 5/9 dosing, and every 9 weeks (± 1 week) for the qd 5/2 treatment schedule, respectively, using computed tomography or magnetic resonance imaging of the chest and abdomen or pelvis.Archived tumor tissue of patients who consented and for whom a valid test result was obtained (n = 28) was analyzed using the Foundation Medicine (FMI) next-generation sequencing (NGS) platform to assess correlations between genomic profile and clinical outcomes [